Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Reference Center Rare Diseases ‘Genetic Sensory Diseases’, MAOLYA, Montpellier, France

In this page

How to contact the center

Full member

HCP Center

Labelized in 2004, MAOLYA is a national reference center for the diagnosis and management of multisensory inherited diseases with isolated or associated ocular, hearing and neurological involvements in children and adults. In regards with this specificity, Maolya and ARAMAV, a specialized and national low vision rehabilitation center developed a global care program and network (Rush) with the collaboration of deaf rehabilitation services for Usher patients that are affected by a congenital hearing loss followed by a progressive retinitis pigmentosa. In the same way, a multidisciplinary outclinic visit is proposed for patients with Wolfram disease.

Picture: Vpe

Contact

Reference Center Rare Diseases ‘Genetic Sensory Diseases’, MAOLYA, Montpellier, France

Hôpital Gui de ChauliacService Ophtalmologie80, avenue Augustin Fliche 1er étage, bureau 1414
34 295 Montpellier Cedex 5
France

Team

Pr Isabelle MEUNIER

Representative

France

Retinal Rare Eye Diseases (WG1)
See more

Dr Catherine Blanchet

France

Retinal Rare Eye Diseases (WG1)
See more

Dr Agathe Robertie

France

Retinal Rare Eye Diseases (WG1)
See more

Dr Anne-Françoise Roux

France

Retinal Rare Eye Diseases (WG1)
See more

Clinical trials

2017-001215-37 - Completed

A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome

Interventional
See the trial
voir la fiche
NCT02994368 - Terminated

A Multicenter Prospective Observational « Natural History » Study in Patients With Choroideremia.

Observational
See the trial
voir la fiche

NCT01235624 - Completed

Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci/Genes.

Interventional
See the trial
voir la fiche
NCT01461213 - Completed

Gene therapy study on choroideremia : to assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in patients with a diagnosis of choroideremia.

Interventional
See the trial
voir la fiche
NCT03328130 - Recruiting, Active

Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression

Interventional
See the trial
voir la fiche
NCT04926129 - Completed

Natural history of the progression of X-linked retinitis pigmentosa.

Observational
See the trial
voir la fiche
NCT03780257 - Completed

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RetinitisPigmentosa Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Interventional
See the trial
voir la fiche
NCT03359551 - Completed

Natural History of the Progression of Choroideremia Study NSR-CHM-OS1.

Observational
See the trial
voir la fiche
NCT03584165 - Recruiting, Active

A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Interventional
See the trial
voir la fiche
NCT00422721 - Completed

Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy.

Interventional
See the trial
voir la fiche
NCT03992417 - Active, Not recruiting

A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis

Observational
See the trial
voir la fiche